Table 1.
Summary of patient and transplantation characteristics
| Characteristics | Category | n | Count (%) |
Median | Min | Max |
|---|---|---|---|---|---|---|
| Site | Fred Hutchinson Cancer Research Center |
567 | 247 (44%) |
|||
| University of Minnesota | 59 (10%) |
|||||
| Dana-Faber Cancer institute |
65 (11%) |
|||||
| Stanford University Medical Center |
72 (13%) |
|||||
| Northwest Children’s Hospital |
13 (2%) | |||||
| Vanderbilt University Medical Center |
47 (8%) | |||||
| Medical College of Wisconsin |
23 (4%) | |||||
| Washington University Medical Center |
4 (1%) | |||||
| Moffitt Cancer Center | 35 (6%) | |||||
| Memorial Sloan- Kettering Cancer Center |
2 (1%) | |||||
| Case type | Incident | 567 | 336 (59%) |
|||
| Prevalent | 231 (41%) |
|||||
| Adult or children | Adult (18+) | 567 | 553 (98%) |
|||
| Ped (2-17) | 14 (2%) | |||||
| Patient age at registration (years) |
567 | 51.0 | 2.0 | 79.0 | ||
| Patient age at transplant (years) |
567 | 50.2 | 1.3 | 78.9 | ||
| Patient gender | Female | 567 | 241 (43%) |
|||
| Male | 326 (57%) |
|||||
| Patient race | Black | 567 | 16 (3%) | |||
| American Indian/Alaskan Native |
2 (<1%) |
|||||
| Asian | 25 (4%) | |||||
| Native Hawaiian/Pacific Islander |
2 (<1%) |
|||||
| White | 510 (90%) |
|||||
| Multi-race | 7 (1%) | |||||
| Unknown | 5 (1%) | |||||
| Ethnicity | Hispanic | 565 | 29 (5%) | |||
| Not Hispanic | 536 (95%) |
|||||
| Months from transplant to enrollment |
567 | 11.9 | 2.9 | 294.2 | ||
| Months from transplant to chronic GVHD onset |
567 | 7.3 | 1.2 | 291 | ||
| Months from chronic GVHD onset to enrollment |
567 | 1.8 | 0 | 32.5 | ||
| Diagnosis | AML | 567 | 190 (34%) |
|||
| ALL | 66 (12%) |
|||||
| CML | 29 (5%) | |||||
| CLL | 46 (8%) | |||||
| MDS | 84 (15%) |
|||||
| NHL | 80 (14%) |
|||||
| HD | 17 (3%) | |||||
| MM | 29 (5%) | |||||
| AA | 7 (1%) | |||||
| Other | 19 (3%) | |||||
| Disease status at transplant | Early | 563 | 184 (33%) |
|||
| Intermediate | 241 (43%) |
|||||
| Advanced | 138 (24%) |
|||||
| Graft source | Bone marrow | 567 | 38 (7%) | |||
| Cord blood | 26 (4%) | |||||
| Peripheral blood | 503 (89%) |
|||||
| Conditioning type | Myeloablative | 564 | 326 (58%) |
|||
| Non-myeloablative | 238 (42%) |
|||||
| Donor-patient CMV status | Patient and donor CMV both negative |
562 | 188 (33%) |
|||
| Patient or donor CMV positive |
374 (67%) |
|||||
| Donor-patient gender combination |
Female into Male | 562 | 164 (29%) |
|||
| Others | 398 (71%) |
|||||
| Donor match | Matched related | 565 | 240 (42%) |
|||
| Matched unrelated | 236 (42%) |
|||||
| Mismatched | 89 (16%) |
|||||
| Prior acute GVHD? | Yes | 567 | 376 (66%) |
|||
| No | 191 (34%) |
|||||
| Karnofsky performance score at onset |
80+ | 567 | 348 (61%) |
|||
| <80 | 95 (17%) |
|||||
| Missing | 124 (22%) |